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Abstract
Background: Acute pulmonary embolism (APE) is a common disease which is associated 
with high mortality and morbidity. Circulating level of copeptin, which was demonstrated to 
be elevated in heart failure, acute myocardial infarction and pulmonary arterial hypertension, 
were reported to be independent predictors of poor outcome in recent studies. The aim of the 
present study was to investigate the clinical utility of copeptin in the diagnosis of APE.
Methods: A total of 90 consecutive patients, admitted to emergency service due to acute chest 
pain and/or dyspnea and who underwent pulmonary computerized tomography angiography 
(CTA) due to suspicion of APE, were included in this prospective study. The patients diag-
nosed with APE were defined as APE (+) group and the remaining individuals with normal 
pulmonary CTA result were defined as APE (–) group.
Results: Copeptin levels (7.76 ± 4.4 vs. 3.81 ± 1.34 ng/dL; p < 0.001) were higher in the 
APE (+) group as compared to the APE (–) group. Copeptin was significantly positively cor-
related with B-type natriuretic peptide (r = 0.434, p < 0.001), D-dimer (r = 0.315, p = 0.003)  
and troponin I (r = 0.300, p = 0.004) and inversely correlated with arterial oxygen satu-
rations (r = –0.533, p < 0001). When the correlation of copeptin with right ventricular 
dysfunction parameters was investigated, it was significantly inversely correlated with the 
tricuspid annular plane systolic excursion (r = –0.521, p < 0.001) and positively cor­
related with right to left ventricle ratio (r = 0.329, p = 0.024). Copeptin (OR 1.836, 95% CI  
1.171–2.878, p = 0.008) was found as a significant independent predictor of APE in  
a multivariate analysis, after adjusting for other risk parameters.
Conclusions: Copeptin is a promising new biomarker, which may be used to support the need 
for further investigations and to improve the diagnosis of patients with APE. (Cardiol J 2016; 
23, 1: 42–50)
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Introduction
Acute pulmonary embolism (APE) is a com-
mon disease which, if not properly diagnosed and 
treated, is associated with significant morbidity 
and mortality rates that can reach 17.4% [1, 2]. As 
the presenting symptoms and signs are nonspe-
cific, diagnostic tests are necessary to establish 
the presence or absence of PE in order to avoid 
the risks of unnecessary anticoagulation or fatal 
thromboembolic recurrence that can occur if APE 
is left untreated [3, 4]. Early diagnosis and risk 
stratification and improved inpatient management 
may yield better short- and long-term prognoses. 
Approximately 30–40% of all APEs are submissive, 
which makes fast and accurate diagnosis of right 
ventricular dysfunction (RVD) crucial for correct 
identification of patients in this high-risk group [5]. 
In addition to evaluation of RVD by 2-dimensional 
(2D) transthoracic echocardiography (TTE), the 
use of inexpensive, easy-to-use and readily availa-
ble measurements of biomarkers may be beneficial. 
Some proven efficacy biomarkers such as D-dimer, 
B-type natriuretic peptide (BNP), and troponin I 
are used in the diagnosis and risk stratification of 
APE [6–9].
Copeptin, the C-terminal portion of pro-vas-
opressin, is a glycosylated polypeptide comprised 
of 39 amino acids and harboring a leucine-rich 
core segment. Since it is part of the uncleaved 
pro-arginine vasopressin (AVP) and emerges equi-
molar to AVP, it can be used as an indirect marker 
for AVP [10]. Copeptin is also co-secreted with 
AVP from the hypothalamus. The diagnostic and 
prognostic utility of copeptin was reported in some 
acute illnesses such as sepsis, pneumonia, lower 
respiratory tract infections, and stroke [11]. In ad-
dition, the usefulness and accuracy of copeptin for 
diagnosis and risk stratification of cardiovascular 
diseases were investigated in recent studies and it 
was found that copeptin combined with troponin T 
enhanced the accuracy in the diagnosis of acute 
myocardial infarction (AMI) and in the prognosis of 
heart failure [12–14]. Furthermore, high copeptin 
levels were reported to be associated with worse 
outcomes in patients who were admitted to the 
Emergency Department with dyspnea [15]. Copep-
tin levels were also demonstrated to be elevated in 
patients with pulmonary arterial hypertension, and 
circulating levels of copeptin were found to be an 
independent predictor of poor patient outcome in 
a recent study [16]. In APE, anatomical obstruction 
and vasoconstriction of pulmonary artery lead to 
an increase in pulmonary vascular resistance and 
results in right ventricular (RV) dilation, while 
neurohumoral activation leads to inotropic and 
chronotropic stimulation [17] and it is likely that 
the AVP system is also activated. As a result, left 
ventricular (LV) filling is impeded in early diastole, 
and this may lead to a reduction of the cardiac 
output and contribute to systemic hypotension and 
hemodynamic instability [18]. According to this 
information, we hypothesized that copeptin, as an 
indirect marker for AVP system, may facilitate the 
diagnosis of APE.
Since there is no data in the literature concern-
ing the clinical utility of copeptin in the diagnosis 
of APE, we aimed at investigating this association 
in the present study.
Methods
A total of 90 consecutive patients, who were 
admitted to emergency service for acute chest 
pain and/or dyspnea and underwent pulmonary 
computerized tomography angiography (CTA) due 
to suspicion of APE between January 2014 and 
February 2015, were included in this prospective 
study. The indications of pulmonary CTA were as 
follows: high clinical probability indicated by ≥ 7 
Wells Score, or low/intermediate clinical prob-
ability indicated by < 7 Wells Score and D-dimer 
level was positive. Exclusion criteria of the present 
study were as follows: sepsis, lung neoplasms, 
end-stage renal failure requiring hemodialysis 
treatment, acute coronary syndromes, acute cer-
ebrovascular disease, acute or chronic aortic dis-
section, decompensated heart failure, surgery or 
bed rest within the past 30 days, prior PE or deep 
venous thrombosis, severe chronic obstructive 
lung disease (FEV1 < 50%), pulmonary hyperten-
sion, acute or chronic infectious diseases, acute 
or chronic inflammatory diseases such as acute 
myocarditis and/or pericarditis, chronic constric-
tive pericarditis, rheumatoid arthritis, systemic 
lupus erythematosus, and vasculitis. The patients 
diagnosed with APE were defined as APE (+) 
group (n = 47) and the remaining individuals with 
normal pulmonary angiography result defined as 
APE (–) group (n = 43).
The demographic, clinical, and laboratory 
characteristics of the study groups were taken 
from the patients’ histories and results of physical 
examinations, which were collected by cardiolo-
gists on admission.
N-terminal B-type natriuretic peptide (NT-
-proBNP), troponin I, D-Dimer, and copeptin serum 
levels were quantified from a venous blood sample, 
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which was drawn early after admission to the Emer-
gency Department. Plasma BNP and troponin I 
concentrations were determined with a chemilu-
minescent microparticle immunoassay using an 
ADVIA Centaur kit  (Henkestrasse 127 D-91052 
Erlangen Germany). D-dimer was measured with 
an enzyme-linked immunosorbent assay (ELISA). 
Hematological parameters were obtained using the 
Coulter LH 780 Hematology Analyzer (Beckman 
Coulter Ireland, Inc., Mervue, and Galway, Ireland).
Serum copeptin levels were measured with 
a commercially available kit using an ELISA (Hu-
man copeptin ELISA kit, Catalogue No: CK-E90208 
Hangzhou East Biopharm CO, Hangzhou, China) 
with a lower sensitivity limit of 0.024 ng/mL. 
Samples were measured in duplicate in a single 
experiment. The intra- and inter-assay coefficients 
of variance of this kit are < 10% and < 12%, re-
spectively. The detection range of copeptin was 
0.05–20 ng/mL.
All of the study patients underwent echocar-
diographic examinations. These examinations were 
performed by 2 expert cardiologists, who were 
fully independent from the study and diagnosis of 
patients, within 24 h after the onset of symptoms.
TTE 2D was performed using a Vivid S6 
device with a 3.5 MHz phased array transducer 
(GE Medical Systems, Horten, Norway) to evalu-
ate RV dimensions and function. 2D studies were 
performed with the patient in the left lateral decu-
bitus position and using conventional (parasternal 
long- and short-axis, apical 4-chamber) views [19].
The tricuspid annular plane systolic excursion 
(TAPSE) was measured as the distance of systolic 
movement of the RV tricuspid annular segment 
along its longitudinal plane. The RV fractional area 
change (RVFAC) was calculated from the apical 
4-chamber view using the percentage change in 
areas of the end-diastolic and end-systolic areas of 
the RV. McConnell’s sign was defined as hypoki-
nesia of the infundibular RV region with normal 
contraction of the RV apex. RV dimensions were 
measured from an RV-focused apical 4-chamber 
view [13]. Specifically, the RV was evaluated for 
the presence or absence of the following signs: RV 
diameter > 35 mm or RV/LV end-diastolic ratio 
> 1 from the apical 4-chamber view; RVFAC < 35%; 
and TAPSE < 15 mm. A diagnosis of RVD was 
established in the presence of 2 or more of these 
criteria.
Pulmonary CTA was carried out using a dual-
source CT system (Definition Flash, Siemens Me-
dical Solution, Forchheim, Germany) with 280 ms 
of rotation time, 2 × 128 slices, a pitch of 3.4 and 
60% of the R-R interval. The tube current for the 
protocol was set at 180–300 mAs and 0.6 mm slice 
collimation was used. Non-ionic contrast reagent 
(Iomeron 400 mgI/mL; Bracco, Milan, Italy) was 
administered at a rate of 5 mL/s (80–100 mL to-
tal) through an 18-gauge needle positioned in the 
antecubital vein using a dual-head power injector. 
Images were obtained during a single interval of 
6 s in which the patient held his or her breath using 
the bolus tracking technique.
The study protocol was approved by the local 
Ethics Committee and all patients provided their 
informed consent. The study was conducted in 
accordance with the ethical principles described 
by the Declaration of Helsinki.
Statistical analysis
Continuous, normally distributed variables 
were presented as mean ± standard deviation. 
Categorical variables were presented as frequen-
cies and/or percentages. The Kolmogorov-Smirnov 
test was used to evaluate whether the continuous 
variables were normally distributed. The Student’s 
t-test was used for the comparison of normal ly 
distributed continuous numerical variables, the 
Mann-Whitney U-test was used for non-normally 
distributed numerical variables, and the c2-test 
was used to compare categorical variables between 
the two groups. Any correlation between data 
was tested by a Spearman or Pearson correla-
tion analysis. A receiver operating characteristic 
analysis was performed to investigate the diag-
nostic value of serum copeptin, D-dimer, troponin, 
and NT-proBNP levels in differentiating patients 
with APE from those with other causes of acute 
dyspnea. A univariate and backward stepwise 
multivariate logistic regression analysis, which 
included variables with a p-value of less than 0.1 
and the respective odds ratios (OR) with 95% con-
fidence intervals (CI) were performed to identify 
independent predictors of APE. A p value < 0.05 
was considered statistically significant. Analysis 
was performed using SPSS version 17.0.0 (SPSS 
Inc., Chicago, IL).
Results
The study population available for analysis 
consisted of 90 patients with a mean age of 
57 ± 16 years. Forty-seven (52.2%) patients were 
diagnosed with APE and 43 (47.7%) patients had 
normal pulmonary angiography. Fourteen (29.7%) 
patients in the APE group were taking thrombolytic 
treatment, 33 (70.3%) patients were treated with 
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heparin according to the current guideline [20]. 
The demographic, clinical, laboratory and echocar-
diographic characteristics of the study groups are 
presented in Table 1. There was no difference be-
tween the two groups in terms of demographic and 
clinical parameters except heart rate and oxygen 
saturation. Heart rates were significantly higher in 
the APE (+) group compared to the APE (–) group 
(p = 0.02). However, oxygen saturations (SaO2) 
were found to be significantly lower in the APE (+) 
group than in the APE (–) group (p < 0.001).
When the echocardiographic parameters of 
the APE (+) and APE (–) groups were compared, 
the RV diameter was significantly larger (3.5 ± 0.7 
vs. 3.0 ± 0.7 cm; p = 0.002, respectively) and Mc-
Connell’s sign was more frequently observed in 
the patients with APE compared to those without 
(19.1% vs. 4.7%; p = 0.036). The APE (+) group 
has worse RV systolic function compared to the 
APE (–) group.
RVFAC and TAPSE were detected as being 
lower in the APE (+) group than in the APE (–) 
group (42 ± 12 vs. 48 ± 10; p = 0.031 and 1.76 
± 0.48 vs. 2.23 ± 0.48; p < 0.001, respectively). 
Moreover, the rate of RV hypertrophy was signifi-
cantly higher in the APE (+) group than the APE (–) 
group (19% vs. 5%, p = 0.036).
The serum levels of copeptin (7.76 ± 4.4 vs. 
3.81 ± 1.34 ng/dL; p < 0.001), troponin I (0.36 ± 
± 0.48 vs. 0.13 ± 0.28 ng/mL; p < 0.008), BNP 
(494 ± 357 vs. 173 ± 258 pg/mL; p < 0.001), and 
D-dimer (4,239 ± 3,048 vs. 1,773 ± 2,545 ng/mL; 
p < 0.001) were demonstrated to be higher in the 
APE (+) group as compared to the APE (–) group.
Table 1. Demographic, clinical, laboratory and echocardiographic characteristics of the study patients.
APE (+) (n = 47) APE (–) (n = 43) P
Age [years] 57 ± 16 58 ± 16 0.710
Male gender [n, %] 25 (53%) 20 (46%) 0.527
Systolic blood pressure [mm Hg] 129 ± 19 132 ± 22 0.807
Diastolic blood pressure [mm Hg] 76 ± 13 77 ± 12 0.688
Oxygen saturation in room air [%] 89.6 ± 4.51 91.8 ± 13 < 0.001
Heart rate [bpm] 97 ± 24 89 ± 19 0.022
Surgery within 30 days [n, %] 13 (28%) 16 (37%) 0.330
Bed rest for > 3 days within 30 days [n, %] 16 (34%) 14 (32%) 0.881
Prior thromboembolism [n, %] 14 (30%) 8 (18%) 0.218
Diabetes mellitus [n, %] 10 (21%) 11 (26%) 0.631
Chronic obstructive lung disease [n, %] 11 (23%) 8 (18%) 0.577
Smoking [n, %] 18 (38%) 18 (42%) 0.730
Body mass index [kg/m2] 30 ± 4 29 ± 6 0.186
Glucose [mg/mL] 128.2 ± 38.2 116.3 ± 34.3 0.056
Creatinine [mg/mL] 0.9 ± 0.3 0.9 ± 0.4 0.624
Hematocrit [%] 38.8 ± 5.4 38.0 ± 4.4 0.451
C-reactive protein [mg/L] 43.2 ± 44.4 43.4 ± 53.3 0.328
Copeptin [ng/mL] 7.76  ± 4.4 3.81 ± 1.34 < 0.001
Troponin I [ng/mL] 0.36 ± 0.48 0.13 ± 0.28 < 0.008
D-dimer [ng/mL] 4239 ± 3048 1773 ± 2545 < 0.001
B-type natriuretic peptide [pg/mL] 494 ± 357 173 ± 258 < 0.001
Right ventricular diameter [cm] 3.5 ± 0.7 3.0 ± 0.7 0.002
RVFAC [%] 42 ± 12 48 ± 10 0.031
Left ventricular ejection fraction [%] 55 ± 10 58 ± 10 0.055
RV/LV ratio 0.78 ± 0.15 0.73 ± 0.13 0.082
TAPSE [mm] 1.76 ± 0.48 2.23 ± 0.48 < 0.001
Right ventricular hypokinesis [n, %] 9 (19%) 2 (5%) 0.036
Values are presented as means ± standard deviation or number (%), as appropriate; APE — acute pulmonary embolism; RVFAC — right 
ventricular fractional area change; RV/LV ratio — right ventricular to left ventricular diameter ratio; TAPSE — tricuspid annular plane systolic 
excursion
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A receiver operating characteristic curve was 
generated for sensitivity and specificity, and the 
respective areas under the curve (AUCs) were 
used to investigate the diagnostic value of serum 
copeptin, D-dimer, troponin, and BNP levels in 
differentiating patients with APE from those with 
other causes of acute dyspnea (Table 2, Fig. 1). 
The analysis indicated that copeptin levels > 4.84 
had a 68.1% sensitivity and 83.7% specificity for 
predicting APE (AUC 0.836, 95% CI 0.755–0.917; 
p < 0.001). Their negative and positive predic-
tive values were 82.1% and 70.6%, respectively. 
D-dimer levels > 1,041.5 had an 85.1% sensitivity 
and 60.5% specificity (AUC 0.794, 95% CI 0.697– 
–0.892; p < 0.001). Their negative and positive pre-
dictive values were 70.2% and 78.8%, respectively. 
BNP levels > 247.4 had a 74.5% sensitivity and 
81.4% specificity (AUC 0.827, 95% CI 0.734–0.919; 
p < 0.001). Their negative and positive predictive 
values were 81.4% and 74.5, respectively. Finally, 
troponin I levels > 0.065 had a 63.8% sensitivity 
and 76.7% specificity for prediction of APE (AUC 
0.733, 95% CI 0.629–0.837; p < 0.001) with 75% 
and 66% positive and negative predictive values, 
respectively.
When the correlations of study biomarkers 
with RV parameters were investigated, copeptin 
was significantly inversely correlated with TAPSE 
(r = –0.521, p < 0.001) and positively correlated 
with RV/LV ratio (r = 0.329, p = 0.024). Moreover, 
copeptin was significantly positively correlated with 
BNP (r = 0.434, p < 0.001), D-dimer (r = 0.315, 
p = 0.003) and troponin I (r = 0.300, p = 0.004) 
(Figs. 2A–C, Table 3). Furthermore, there was 
a significant negative correlation between SaO2 and 
copeptin (r = –0.533, p < 0001).
In a univariate regression analysis, copeptin, 
troponin I, D-dimer, BNP, TAPSE, RV diameter, 
SaO2 and heart rate were significantly associated 
with APE. Copeptin (OR 1.836, 95% CI 1.171– 
–2.878, p = 0.008) and D-dimer (OR 1.000, 95% 
CI 1.000–1.001, p = 0.003) were found to be 
significant independent predictors of APE in 
a multivariate analysis, after adjusting for other 
risk parameters (Table 4).
The APE (+) group was divided into two 
subgroups according to the presence or absence 
of acute RV failure. Fifteen out of the 47 patients 
(31%) with APE had acute RV failure. Levels of 
copeptin (p = 0.02), troponin I (p = 0.02), D-dimer 
(p = 0.01), and BNP (p = 0.001) were higher in the 
patients with RV failure compared to the patients 
with normal RV function (Table 5).
Discussion
The main findings of the present study were as 
follows: 1) copeptin levels were demonstrated to be 
higher in the APE (+) group compared to the APE (–) 
group; 2) copeptin was significantly inversely 
Table 2. The receiver operating characteristic curve for copeptin, troponin I, D-dimer and B-type natriu-
retic peptide (BNP) for predicting acute pulmonary embolism.
Variable AUC P SE 95% CI Sensitivity Specificity PPD NPD
Copeptin 0.836 < 0.001 0.041 0.755-0.917 68.1% 83.7% 82.1% 70.6%
Troponin I 0.733 < 0.001 0.053 0.629-0.837 63.8 % 76.7% 75.0% 66.0%
D-dimer 0,794 < 0.001 0.050 0,697-0.892 85.1 % 60.5% 70.2% 78.8%
BNP 0.827 < 0.001 0.047 0.734-0.919 74.5 % 81.4% 81.4% 74.5%
AUC — area under the curve; SE — standard error; CI — confidence interval; PPD — positive predictive diameter; NPD — negative predictive 
diameter
Figure 1. The receiver operating characteristic curve for 
copeptin, troponin I, D-dimer and B-type natriuretic pep-
tide (BNP) for predicting acute pulmonary embolism.
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Figure 2. The correlations of copeptin with B-type 
natriuretic peptide (BNP) (A); with D-dimer (B); with 
troponin-I (C).
correlated with TAPSE and positively correlated 
with RV/LV ratio, BNP, D-dimer and troponin I; 
3) copeptin and D-dimer were found to be signifi-
cant independent predictors of APE, after adjusting 
for other risk parameters; 4) copeptin is a potential 
biomarker, which may be used to support the need 
for further investigations, with moderate sensi-
tivity and specificity and 5) copeptin, troponin I, 
D-dimer, and BNP levels were significantly higher 
in the patients with acute RV failure due to APE 
as compared to patients with normal RV function.
Effective strategies for risk stratification and 
diagnosis in patients with APE are crucial and bio-
markers such as D-dimer and troponin I could be 
used to diagnose APE, especially in patients who 
are in the low/intermediate risk group [6].
Copeptin, the C-terminal part of the vaso-
pressin prohormone, has emerged as a promising 
surrogate target for measurement of vasopressin 
concentration and also seems useful in cardio-
vascular disease [12–15]. In previous studies, the 
prognostic and diagnostic accuracy of copeptin 
were analyzed in acute coronary syndrome, heart 
failure, and pulmonary hypertension [12–16]. 
A strong relationship between copeptin levels and 
short- and long-term mortality in patients who 
were referred to the Emergency Department was 
also reported in a recent study [21].
The present study is the first to investigate the 
clinical utility of copeptin in the diagnosis of APE. 
In this study, copeptin was found to be a significant 
independent predictor of APE, after adjusting for 
other risk parameters. In addition, biomarkers re-
lated to APE such as BNP, D-dimer, and troponin I 
had been evaluated previously and were found to 
be higher in patients with APE, which is consistent 
with the results of our study.
When the diagnostic value of study biomark-
ers were compared, copeptin was the most specific 
marker for APE, with 83.7% specificity and 82.1% 
positive predictive value. Moreover, D-dimer was 
the most sensitive biomarker for APE, with 85.1% 
sensitivity and 78.8% negative predictive value. 
Although D-dimer values may be used to exclude 
PE in patients with either a low or a moderate 
probability of PE, measurement of D-dimer is not 
useful for confirming PE [22–25]. Copeptin may be 
used to support the need for further investigations 
with moderate specificity and positive predictive 
value. However, it will not be replacing pulmonary 
CTA or spiral thorax CT as a diagnostic tool of APE.
In previous studies, increased BNP levels 
were demonstrated to be associated with adverse 
outcomes and RVD in patients with APE [26–27]. 
48 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 1
Ohigashi et al. [26] investigated the role of BNP, 
D-dimer, troponin I, and C-reactive protein in 
predicting adverse outcomes and RVD in patients 
with APE and they demonstrated that only high 
plasma BNP level was found to be a predictor of 
RVD and short- and long-term prognosis of APE. 
In the present study, all of the parameters were 
found to be higher in the patients with acute RVD. 
However, only plasma BNP levels were found to 
be significantly correlated with all the echocar-
diographic parameters that are used for diagnosis 
of acute RVD. While D-dimer was only correlated 
with RVFAC, copeptin was found to be correlated 
with TAPSE and RV/LV ratio.
Table 4. Univariate and multivariate regression analyses of predictors of acute pulmonary embolism.
Univariate Multivariate
P OR 95% CI P OR 95% CI
Copeptin 0.008  1.836 1.171–2.878 0.008 1.836 1.171–2.878
Troponin I 0.017 6.985 1.423–3.4303 0.658 0.648 0.095–4.424
D-dimer < 0.001 1.000 1.000–1.001 0.003 1.000 1.000–1.001
BNP < 0.001 1.004 1.002–1.006 0.088 1.002 1.000–1.005
SaO2 0.005 0.853 0.764-0.953 0.780 1.026 0.859-1.225
TAPSE < 0.001 0.117 0.038–0.360 0.175 0.304 0.054–1.700
Age 0.769 0.996 0.970–1.023
RV diameter 0.003 2.602 1.382–4.901 0.724 1.193 0.448–3.180
Heart rate 0.02 1.026 1.004–1.048 0.078 1.028 0.997–1.059
SBP 0.390 0.991 0.971–1.011
CI — confidence interval; OR — odds ratio; BNP — B-type natriuretic peptide; SaO2 — oxygen saturation, TAPSE — tricuspid annular plane 
systolic excursion; RV — right ventricular, SBP — systolic blood pressure
Table 5. Comparison of the study biomarkers levels between with and without right ventricular dys-
function (RVD) in patients with acute pulmonary embolism (APE).
APE with RVD (n = 15) APE without RVD (n = 32) P
Copeptin [ng/dL] 9.36 ± 4.61 6.94 ± 4.14 0.020
Troponin I [ng/dL] 0.48 ± 0.40 0.30 ± 0.51 0.029
D-dimer [ng/dL] 6,032 ± 3,313 3,398 ± 2,557 0.010
B-type natriuretic peptide [ng/dL] 684 ± 299 405 ± 351 0.001
Table 3. Correlation analysis between study biomarkers and right ventricular parameters.
RV diameter RVFAC TAPSE RV/LV ratio
Copeptin r 0.275 –0.262 –0.521 0.329
p 0.061 0.076 < 0.0001 0.024
Troponin I r 0.042 –0.246 –0.155 0.178
p 0.780 0.096 0.298 0.233
D-dimer r 0.164 –0,350 –0.223 0.272
p 0.271 0.016 0.132 0.065
BNP r 0.423 –0.483 –0.416 0.278
p 0.003 0.001 0.004 0.059
RV — right ventricular; RVFAC — RV fractional area change; TAPSE — tricuspid annular plane systolic excursion, RV/LV ratio — RV to left ven-
tricular diameter ratio; BNP — B-type natriuretic peptide
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Vasopressin is an antidiuretic and vasocon-
strictive hormone, whose levels of circulating 
form underlie a complex feedforward and feedback 
regulation. Among the stimuli that lead to vaso-
pressin release are increased plasma osmolality, 
decreased arterial pressure, reduced cardiac filling, 
and neurohumoral peptides such as angiotensin 
[28]. Levels of vasopressin have been shown to be 
elevated in heart failure [29]. Copeptin is secreted 
stoichiometrically with vasopressin from the neu-
rohypophysis and is much more stable, thus over-
coming the limitations and difficulties of assessing 
the arginine-vasopressin system [30]. It is reported 
that copeptin is strongly associated with severity 
and long-term prognosis of left ventricular heart 
failure [29]. Nickel et al. [16] reported increased 
levels of copeptin in patients with pulmonary 
hypertension and RV failure. Increased copeptin 
levels were linked to increased neurohumoral acti-
vation due to RV failure in patients with pulmonary 
artery hypertension. In our study, copeptin was 
higher in the patients with APE and it was also 
found in increased amounts in the patients with 
RVD compared to those without RVD. Elevated 
levels of copeptin in the patients with APE might 
be due to acute right heart overload and failure and 
raised neurohumoral activation. Since it is known 
that RVD is a poor prognostic factor in patients 
with APE, assessing copeptin levels on admission 
might be useful for performing a risk stratification 
of the patients with APE.
Limitations of the study
The present study has some limitations. First, 
the study population was relatively small; however, 
we were still able to demonstrate a strong relation-
ship between increased copeptin levels and the pres-
ence of APE and RVD. Second, a lack of short- and 
long-term follow-up of patients was another limitation 
to this study. Third, because of a single measurement 
on admission, the changes in copeptin in response 
to treatment could not be evaluated. Fourth, there 
are some issues in terms of cost and timeliness of 
copeptin assays. The cost-effectiveness of copeptin 
assays is controversial in the literature. Further-
more, it may take more than 24 h to come back or 
it will have to be sent elsewhere to study this assay. 
These disadvantages of copeptin assays may reduce 
the clinical utility of this new biomarker routinely 
in APE [31, 32]. The last limitation of the present 
study was having many exclusion criteria limiting 
generalizability. The patients who are a challenge to 
diagnose are often the ones who might have conges-
tive heart failure or chronic obstructive lung disease 
or an inflammatory disorder. Because of many exclu-
sion criteria, our results cannot be extrapolated to all 
patients with APE.
Conclusions
This study is the first to demonstrate a diagnos-
tic value of copeptin in patients with APE. Copeptin 
was found an independent significant predictor of 
APE, even after adjustments for various risk param-
eters. Copeptin is a promising new biomarker, which 
may be used to support the need for further investi-
gations and to improve the diagnosis of patients with 
APE, with moderate sensitivity and specificity. Since 
it is not specific to a certain disease, copeptin could 
be used as an adjunct with more specific biomarkers 
where it may increase diagnostic accuracy and aid 
clinicians in making better diagnostic judgements. 
Moreover, a larger study is warranted in a more 
general emergency department population being 
considered for PE without as many exclusions to 
see if copeptin is truly useful or if the early positive 
results will get masked by other diagnoses leading 
to similar elevations in copeptin.
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